$63.16
Live
1.2%
Downside
Day's Volatility :6.87%
Upside
5.73%
0.0%
Downside
52 Weeks Volatility :55.52%
Upside
55.52%
Period | Dexcom, Inc. | Sector (Health Care) | Index (NASDAQ Composite) |
---|---|---|---|
3 Months | -13.26% | 6.5% | 7.9% |
6 Months | -11.57% | 7.1% | 11.2% |
1 Year | -17.48% | 9.8% | 21.6% |
3 Years | -4.68% | 14.2% | 15.8% |
Market Capitalization | 42.9B |
Book Value | $5.67 |
Earnings Per Share (EPS) | 1.55 |
PE Ratio | 69.58 |
PEG Ratio | 2.53 |
Wall Street Target Price | 151.17 |
Profit Margin | 16.82% |
Operating Margin TTM | 10.98% |
Return On Assets TTM | 6.79% |
Return On Equity TTM | 28.54% |
Revenue TTM | 3.8B |
Revenue Per Share TTM | 9.83 |
Quarterly Revenue Growth YOY | 24.2% |
Gross Profit TTM | 1.9B |
EBITDA | 848.5M |
Diluted Eps TTM | 1.55 |
Quarterly Earnings Growth YOY | 1.99 |
EPS Estimate Current Year | 1.79 |
EPS Estimate Next Year | 2.25 |
EPS Estimate Current Quarter | 0.27 |
EPS Estimate Next Quarter | 0.39 |
What analysts predicted
Upside of 139.34%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.0B | ↑ 43.58% |
Net Income | -127.1M | ↑ 153.19% |
Net Profit Margin | -12.32% | ↓ 5.33% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.5B | ↑ 43.08% |
Net Income | 101.1M | ↓ 179.54% |
Net Profit Margin | 6.85% | ↑ 19.17% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.9B | ↑ 30.54% |
Net Income | 493.6M | ↑ 388.23% |
Net Profit Margin | 25.62% | ↑ 18.77% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 2.4B | ↑ 27.08% |
Net Income | 154.7M | ↓ 68.66% |
Net Profit Margin | 6.32% | ↓ 19.3% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.9B | ↑ 18.84% |
Net Income | 341.2M | ↑ 120.56% |
Net Profit Margin | 11.73% | ↑ 5.41% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 3.6B | ↑ 24.49% |
Net Income | 541.5M | ↑ 58.7% |
Net Profit Margin | 14.95% | ↑ 3.22% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 815.2M | ↑ 5.93% |
Net Income | 91.8M | ↓ 9.29% |
Net Profit Margin | 11.26% | ↓ 1.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 741.5M | ↓ 9.04% |
Net Income | 48.6M | ↓ 47.06% |
Net Profit Margin | 6.55% | ↓ 4.71% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 871.3M | ↑ 17.51% |
Net Income | 115.9M | ↑ 138.48% |
Net Profit Margin | 13.3% | ↑ 6.75% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 975.0M | ↑ 11.9% |
Net Income | 120.7M | ↑ 4.14% |
Net Profit Margin | 12.38% | ↓ 0.92% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↑ 6.1% |
Net Income | 256.3M | ↑ 112.34% |
Net Profit Margin | 24.78% | ↑ 12.4% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 921.0M | ↓ 10.97% |
Net Income | 146.4M | ↓ 42.88% |
Net Profit Margin | 15.9% | ↓ 8.88% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 111.92% |
Total Liabilities | 1.3B | ↑ 158.45% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↑ 25.0% |
Total Liabilities | 1.5B | ↑ 20.73% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 4.3B | ↑ 79.14% |
Total Liabilities | 2.5B | ↑ 62.92% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 4.9B | ↑ 13.36% |
Total Liabilities | 2.6B | ↑ 6.01% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 5.4B | ↑ 10.86% |
Total Liabilities | 3.3B | ↑ 24.8% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 6.3B | ↑ 16.19% |
Total Liabilities | 4.2B | ↑ 28.71% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 5.4B | ↑ 10.05% |
Total Liabilities | 3.3B | ↑ 6.02% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 5.5B | ↑ 2.3% |
Total Liabilities | 3.3B | ↑ 0.71% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.8B | ↑ 23.66% |
Total Liabilities | 4.7B | ↑ 43.78% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.6B | ↓ 3.29% |
Total Liabilities | 4.3B | ↓ 8.3% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.3B | ↓ 5.03% |
Total Liabilities | 4.2B | ↓ 3.06% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 6.5B | ↑ 3.48% |
Total Liabilities | 4.2B | ↑ 0.94% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 123.2M | ↑ 33.91% |
Investing Cash Flow | -139.8M | ↓ 3.19% |
Financing Cash Flow | 710.4M | ↑ 78.0% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 314.5M | ↑ 155.28% |
Investing Cash Flow | -1.0B | ↑ 626.18% |
Financing Cash Flow | 10.7M | ↓ 98.49% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 475.6M | ↑ 51.22% |
Investing Cash Flow | -1.0B | ↑ 0.28% |
Financing Cash Flow | 912.1M | ↑ 8424.3% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 442.5M | ↓ 6.96% |
Investing Cash Flow | -216.1M | ↓ 78.77% |
Financing Cash Flow | 10.4M | ↓ 98.86% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 669.5M | ↑ 51.3% |
Investing Cash Flow | -521.5M | ↑ 141.32% |
Financing Cash Flow | -552.5M | ↓ 5412.5% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 132.5M | ↓ 54.81% |
Investing Cash Flow | -194.1M | ↓ 184.65% |
Financing Cash Flow | -1000.0K | ↓ 99.82% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 155.4M | ↑ 17.28% |
Investing Cash Flow | -186.7M | ↓ 3.81% |
Financing Cash Flow | 11.2M | ↓ 1220.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 190.3M | ↑ 22.46% |
Investing Cash Flow | -555.9M | ↑ 197.75% |
Financing Cash Flow | 939.5M | ↑ 8288.39% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 269.2M | ↑ 41.46% |
Investing Cash Flow | -179.5M | ↓ 67.71% |
Financing Cash Flow | -637.4M | ↓ 167.84% |
Sell
Neutral
Buy
Dexcom, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Dexcom, Inc. | -4.99% | -11.57% | -17.48% | -4.68% | 180.55% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Dexcom, Inc. | 69.58 | 69.58 | 2.53 | 1.79 | 0.29 | 0.07 | NA | 5.67 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Dexcom, Inc. | Buy | $42.9B | 180.55% | 69.58 | 16.82% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Dexcom, Inc.
Revenue is down for the last 2 quarters, 1.03B → 921.0M (in $), with an average decrease of 11.0% per quarter
Netprofit is down for the last 2 quarters, 256.3M → 146.4M (in $), with an average decrease of 42.9% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 59.2%
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 73.6%
Vanguard Group Inc
BlackRock Inc
State Street Corporation
Baillie Gifford & Co Limited.
Capital Research Global Investors
Sands Capital Management, LLC
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
Organization | Dexcom, Inc. |
Employees | 9500 |
CEO | Mr. Kevin Ronald Sayer |
Industry | Health Technology |